The FDA has granted approval to lisocabtagene maraleucel (liso-cel) (Breyanzi®, Bristol Myers Squibb™) for treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after one prior therapy who have become R/R within 12 months of first-line therapy, or who have become R/R after the first line of therapy and are not eligible for hematopoietic stem cell transplant (HSCT). The approval was based on the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 PILOT study (NCT0...